Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes

Eldor, 2001, Thrombophilia, thrombosis and pregnancy, Thromb Haemost, 86, 104, 10.1055/s-0037-1616206 Heit, 2005, Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study, Ann Intern Med, 143, 697, 10.7326/0003-4819-143-10-200511150-00006 Gherman, 1999, Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy, Obstet Gynecol, 94, 730, 10.1016/S0029-7844(99)00426-3 de Swiet, 2000, Maternal mortality: confidential enquiries into maternal deaths in the United Kingdom, Am J Obstet Gynecol, 182, 760, 10.1016/S0002-9378(00)70324-3 Andres, 2001, Venous thromboembolism and pregnancy, Obstet Gynecol Clin North Am, 28, 613, 10.1016/S0889-8545(05)70222-9 James, 2005, Thrombosis during pregnancy and the postpartum period, Am J Obstet Gynecol, 193, 216, 10.1016/j.ajog.2004.11.037 Bates, 2004, Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, Chest, 126, 627S, 10.1378/chest.126.3_suppl.627S 2000, Thromboembolism in pregnancy: Clinical management guidelines for obstetricians and gynecologists: American College of Obstetricians and Gynaecologists, 19 2000, Prevention of deep vein thrombosis and pulmonary embolism: American College of Obstetricians and Gynaecologists, 21 Kent, 2000, Prevention and treatment of venous thromboembolism (VTE) in obstetrics, J SOCG, 22, 736 Methods and background. US Preventive Services Task Force. Agency for Healthcare Research and Quality. Rockville, MD. May 2004. Available at: http://www.ahrq.gov/clinic/uspstmeth.htm. Accessed on June 4, 2007. Weg, 1998, Venous thromboembolism in pregnancy, Semin Reprod Crit Care Med, 19, 231, 10.1055/s-2007-1009401 Zakzouk, 1986, The congenital warfarin syndrome, J Laryngol Otol, 100, 215, 10.1017/S0022215100099011 Wong, 1993, Fetal and neonatal outcome of exposure to anticoagulants during pregnancy, Am J Med Genet, 45, 17, 10.1002/ajmg.1320450107 Meschengieser, 1999, Anticoagulation in pregnant women with mechanical heart valve prostheses, Heart, 82, 23, 10.1136/hrt.82.1.23 Orme, 1977, May mothers given warfarin breast-feed their infants?, Br Med J, 1, 1564, 10.1136/bmj.1.6076.1564 Hirsh, 2004, Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, Chest, 126, 188S, 10.1378/chest.126.3_suppl.188S Hunt, 1997, Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies, Thromb Haemost, 77, 39, 10.1055/s-0038-1655903 Frydman, 1996, Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans, Haemostasis, 26, 24 Ellison, 2000, Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy, BJOG, 107, 1116, 10.1111/j.1471-0528.2000.tb11110.x Thomson, 1998, Low-molecular-weight heparin for immediate management of thromboembolic disease in pregnancy, Lancet, 352, 1904, 10.1016/S0140-6736(05)60394-7 Shefras, 1996, Bone density studies in pregnant women receiving heparin, Eur J Obstet Gynecol Reprod Biol, 65, 171, 10.1016/0301-2115(95)02358-5 Warkentin, 1995, Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin, N Engl J Med, 332, 1330, 10.1056/NEJM199505183322003 Laurent, 2002, Low molecular weight heparins: a guide to their optimum use in pregnancy, Drugs, 62, 463, 10.2165/00003495-200262030-00004 Gould, 1999, Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials, Ann Intern Med, 130, 800, 10.7326/0003-4819-130-10-199905180-00003 Aventis. Lovenox. Available at: http://www.aventis-us.com/PIs/lovenox_TXT.html. Accessed on Sept. 1, 2005. Sanson, 1999, Safety of low-molecular-weight heparin in pregnancy: a systematic review, Thromb Haemost, 81, 668, 10.1055/s-0037-1614550 Greer, 2005, Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy, Blood, 106, 401, 10.1182/blood-2005-02-0626 Hayes, 2006, Low molecular weight heparin, the most cost effective treatment of venous thromboembolism, Am J of Obstet Gynecol, 195, S92, 10.1016/j.ajog.2006.10.301 Sanofi-Synthelabo. Arixtra prescribing information. Sanofi-Synthelabo. Available at: http://www.arixtra.com/docs/Arixtra_PI.pdf. Accessed on Sept. 1, 2005. Berlex. Refludan. Berlex prescribing information. Available at: http://www.refludan.com/pdfs/reflupi.pdf. Accessed on Sept. 1, 2005. GlaxoSmithKline. Argatroban prescribing information. GlaxoSmithKline. Available at: http://us.gsk.com/products/assets/us_argatroban.pdf. Accessed on Sept. 1, 2005. The Medicines Company. Angiomax. Available at: 0http://www.themedicinescompany.com/%7Eproducts_content/PN1002-6.pdf. Accessed on Sept. 1, 2005. Greer, 2000, The challenge of thrombophilia in maternal-fetal medicine, N Engl J Med, 342, 424, 10.1056/NEJM200002103420610 Greer, 1997, Epidemiology, risk factors and prophylaxis of venous thrombo-embolism in obstetrics and gynaecology, Baillieres Clin Obstet Gynaecol, 11, 403, 10.1016/S0950-3552(97)80019-3 Greer, 1999, Thrombosis in pregnancy: maternal and fetal issues, Lancet, 353, 1258, 10.1016/S0140-6736(98)10265-9 Lindqvist, 1999, Thrombotic risk during pregnancy: a population study, Obstet Gynecol, 94, 595, 10.1016/S0029-7844(99)00308-7 Andersen, 1998, The cumulative incidence of venous thromboembolism during pregnancy and puerperium—an 11 year Danish population-based study of 63,300 pregnancies, Acta Obstet Gynecol Scand, 77, 170, 10.1080/j.1600-0412.1998.770207.x Hellgren, 1981, Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium, Gynecol Obstet Invest, 12, 141, 10.1159/000299596 Stirling, 1984, Haemostasis in normal pregnancy, Thromb Haemost, 52, 176, 10.1055/s-0038-1661167 Comp, 1986, Functional and immunologic protein S levels are decreased during pregnancy, Blood, 68, 881, 10.1182/blood.V68.4.881.881 Cumming, 1995, Development of resistance to activated protein C during pregnancy, Br J Haematol, 90, 725, 10.1111/j.1365-2141.1995.tb05610.x Lockwood, 2002, Inherited thrombophilias in pregnant patients: detection and treatment paradigm, Obstet Gynecol, 99, 333, 10.1016/S0029-7844(01)01760-4 Kruithof, 1987, Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors, Blood, 69, 460, 10.1182/blood.V69.2.460.460 Ku, 2003, Circulating levels of inflammatory cytokines (IL-1 beta and TNF-alpha), resistance to activated protein C, thrombin and fibrin generation in uncomplicated pregnancies, Thromb Haemost, 90, 1074, 10.1160/TH03-02-0119 Brill-Edwards, 2000, Safety of withholding heparin in pregnant women with a history of venous thromboembolism: recurrence of clot in this pregnancy study group, N Engl J Med, 343, 1439, 10.1056/NEJM200011163432002 Pabinger, 2005, Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis, J Thromb Haemost, 3, 949, 10.1111/j.1538-7836.2005.01307.x Tengborn, 1989, Recurrent thromboembolism in pregnancy and puerperium, Am J Obstet Gynecol, 160, 90, 10.1016/0002-9378(89)90095-1 Eichinger, 1999, Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden, Thromb Haemost, 82, 1232, 10.1055/s-0037-1614366 Chunilal, 2002, The APTT response of pregnant plasma to unfractionated heparin, Thromb Haemost, 87, 92, 10.1055/s-0037-1612949 Pabinger, 2002, Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism, Blood, 100, 1060, 10.1182/blood-2002-01-0149 Dahlback, 1994, Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene, Haemostasis, 24, 139 Ridker, 1997, Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening, JAMA, 277, 1305, 10.1001/jama.1997.03540400055031 Lockwood, 2001, Inherited thrombophilias in pregnant patients, Prenat Neonat Med, 6, 3 Voorberg, 1994, Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V, Lancet, 343, 1535, 10.1016/S0140-6736(94)92939-4 Kupferminc, 1999, Increased frequency of genetic thrombophilia in women with complications of pregnancy, N Engl J Med, 340, 9, 10.1056/NEJM199901073400102 Gerhardt, 2000, Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium, N Engl J Med, 342, 374, 10.1056/NEJM200002103420602 Gonzalez-Porras, 2006, Risk of recurrent venous thrombosis in patients with G20210A mutation in the prothrombin gene or factor V Leiden mutation, Blood Coagul Fibrinolysis, 17, 23, 10.1097/01.mbc.0000201488.33143.09 Infante-Rivard, 2002, Absence of association of thrombophilia polymorphisms with intrauterine growth restriction, N Engl J Med, 347, 19, 10.1056/NEJM200207043470105 Nelen, 2000, Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis, Fertil Steril, 74, 1196, 10.1016/S0015-0282(00)01595-8 Francis, 2002, Plasminogen activator inhibitor-1 levels and polymorphisms, Arch Pathol Lab Med, 126, 1401, 10.5858/2002-126-1401-PAILAP Martinelli, 2001, Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia, Thromb Haemost, 86, 800, 10.1055/s-0037-1616134 Hellgren, 1995, Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives, Am J Obstet Gynecol, 173, 210, 10.1016/0002-9378(95)90192-2 Hirsch, 1996, Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden, Am Heart J, 131, 1145, 10.1016/S0002-8703(96)90089-7 Kondle, 2003, Thrombosis: diagnosis and management: Issues before, during and after labor, Vol III, 525 Martinelli, 1996, Heightened thrombin generation in individuals with resistance to activated protein C, Thromb Haemost, 75, 703, 10.1055/s-0038-1650351 Zoller, 1996, Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency, Thromb Haemost, 75, 270, 10.1055/s-0038-1650259 Simioni, 1996, Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation, Br J Haematol, 92, 435, 10.1046/j.1365-2141.1996.d01-1500.x Samama, 2000, An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study, Arch Intern Med, 160, 3415, 10.1001/archinte.160.22.3415 Hellgren, 2003, Hemostasis during normal pregnancy and puerperium, Semin Thromb Hemost, 29, 125, 10.1055/s-2003-38897 Juhan-Vague, 1991, Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis, Diabetologia, 34, 457, 10.1007/BF00403280 Bremme, 1992, Enhanced thrombin generation and fibrinolytic activity in the normal pregnancy and puerperium, Obstet Gynecol, 80, 132 Sebire, 2001, Maternal obesity and pregnancy outcome: a study of 287,213 pregnancies in London, Int J Obes Relat Metab Disord, 25, 1175, 10.1038/sj.ijo.0801670 Cedergren, 2004, Maternal morbid obesity and the risk of adverse pregnancy outcome, Obstet Gynecol, 103, 219, 10.1097/01.AOG.0000107291.46159.00 Geerts, 2004, Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, Chest, 126, 338S, 10.1378/chest.126.3_suppl.338S Martinelli, 1998, Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families, Blood, 92, 2353, 10.1182/blood.V92.7.2353 Danilenko-Dixon, 2001, Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or post partum: a population-based, case-control study, Am J Obstet Gynecol, 184, 104, 10.1067/mob.2001.107919 Anderson, 2003, Risk factors for venous thromboembolism, Circulation, 107, I9 Paidas, 2004, Screening and management of inherited thrombophilias in the setting of adverse pregnancy outcome, Clin Perinatol, 31, 783, 10.1016/j.clp.2004.07.002 Kupferminc, 2000, Severe preeclampsia and high frequency of genetic thrombophilic mutations, Obstet Gynecol, 96, 45, 10.1016/S0029-7844(00)00861-9 Howley, 2005, A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction, Am J Obstet Gynecol, 192, 694, 10.1016/j.ajog.2004.09.011 Alfirevic, 2002, How strong is the association between maternal thrombophilia and adverse pregnancy outcome?, Eur J Obstet Gynecol Reprod Biol, 101, 6, 10.1016/S0301-2115(01)00496-1 Robertson, 2006, The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study, Br J Haematol, 132, 171, 10.1111/j.1365-2141.2005.05847.x van Pampus, 1999, High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia, Am J Obstet Gynecol, 180, 1146, 10.1016/S0002-9378(99)70608-3 Krauss, 1998, Activated protein C resistance and factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelets syndrome, Obstet Gynecol, 92, 457, 10.1016/S0029-7844(98)00208-7 Nagy, 1998, Detection of factor V Leiden mutation in severe pre-eclamptic Hungarian women, Clin Genet, 53, 478, 10.1111/j.1399-0004.1998.tb02599.x De Groot, 1999, Preeclampsia and genetic risk factors for thrombosis: a case-control study, Am J Obstet Gynecol, 181, 975, 10.1016/S0002-9378(99)70335-2 Livingston, 2001, Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia, Am J Obstet Gynecol, 185, 153, 10.1067/mob.2001.114691 Currie, 2002, Is there an increased maternal-infant prevalence of factor V Leiden in association with severe pre-eclampsia?, BJOG, 109, 191 Benedetto, 2002, Factor V Leiden and factor II G20210A in preeclampsia and HELLP syndrome, Acta Obstet Gynecol Scand, 81, 1095, 10.1034/j.1600-0412.2002.811201.x Schlembach, 2003, Association of maternal and/or fetal factor V Leiden and G20210A prothrombin mutation with HELLP syndrome and intrauterine growth restriction, Clin Sci (Lond), 105, 279, 10.1042/CS20030073 Kim, 2001, Am J Obstet Gynecol, 184, 1211, 10.1067/mob.2001.110411 von Tempelhoff, 2000, Incidence of the factor V Leiden-mutation, coagulation inhibitor deficiency, and elevated antiphospholipid-antibodies in patients with preeclampsia or HELLP-syndrome: hemolysis, elevated liver-enzymes, low platelets, Thromb Res, 100, 363, 10.1016/S0049-3848(00)00312-1 Kupferminc, 2000, High prevalence of the prothrombin gene mutation in women with intrauterine growth retardation, abruptio placentae and second trimester loss, Acta Obstet Gynecol Scand, 79, 963, 10.3109/00016340009169243 Dizon-Townson, 1996, The factor V Leiden mutation may predispose women to severe preeclampsia, Am J Obstet Gynecol, 175, 902, 10.1016/S0002-9378(96)80022-6 Addis, 2001, Fetal effects of cocaine: an updated meta-analysis, Reprod Toxicol, 15, 341, 10.1016/S0890-6238(01)00136-8 de Vries, 1997, Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies, BJOG, 104, 1248, 10.1111/j.1471-0528.1997.tb10970.x Nowak-Gottl, 2000, Evaluation of lipoprotein(a) and genetic prothrombotic risk factors in patients with recurrent foetal loss, Thromb Haemost, 83, 350, 10.1055/s-0037-1613815 Roque, 2004, Maternal thrombophilias are not associated with early pregnancy loss, Thromb Haemost, 91, 290, 10.1160/TH03-09-0596 Many, 2002, Third-trimester unexplained intrauterine fetal death is associated with inherited thrombophilia, Obstet Gynecol, 99, 684, 10.1016/S0029-7844(02)01938-5 Rai, 2002, Factor V Leiden and recurrent miscarriage-prospective outcome of untreated pregnancies, Hum Reprod, 17, 442, 10.1093/humrep/17.2.442 Gris, 1999, Case-control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent—the Nimes Obstetricians and Haematologists Study 5 (NOHA5), Thromb Haemost, 81, 891, 10.1055/s-0037-1614594 Rey, 2003, Thrombophilic disorders and fetal loss: a meta-analysis, Lancet, 361, 901, 10.1016/S0140-6736(03)12771-7 Martinelli, 2000, Mutations in coagulation factors in women with unexplained late fetal loss, N Engl J Med, 343, 1015, 10.1056/NEJM200010053431405 Hefler, 2004, Genetic polymorphisms associated with thrombophilia and vascular disease in women with unexplained late intrauterine fetal death: a multicenter study, J Soc Gynecol Investig, 11, 42, 10.1016/j.jsgi.2003.07.008 Mello, 1999, Usefulness of screening for congenital or acquired hemostatic abnormalities in women with previous complicated pregnancies, Haemostasis, 29, 197 Grandone, 1997, Factor V Leiden is associated with repeated and recurrent unexplained fetal losses, Thromb Haemost, 77, 822, 10.1055/s-0038-1656060 Alonso, 2002, Acquired and inherited thrombophilia in women with unexplained fetal losses, Am J Obstet Gynecol, 187, 1337, 10.1067/mob.2002.126849 Larsen, 1998, The Arg506Gln mutation (FV Leiden) among a cohort of 4188 unselected Danish newborns, Thromb Res, 89, 211, 10.1016/S0049-3848(98)00010-3 Volzke, 2003, Factor V Leiden and the risk of stillbirth in a German population, Thromb Haemost, 90, 429, 10.1160/TH03-02-0117 Clark, 2001, The Glasgow Outcome, APCR and Lipid (Goal) Pregnancy Study: significance of pregnancy associated activated protein C resistance, Thromb Haemost, 85, 30, 10.1055/s-0037-1612659 Paidas, 2005, Protein Z, protein S levels are lower in patients with thrombophilia and subsequent pregnancy complications, J Thromb Haemost, 3, 497, 10.1111/j.1538-7836.2005.01158.x Laude, 2001, Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight, Thromb Haemost, 85, 18, 10.1055/s-0037-1612657 Gris, 2004, Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder, Blood, 103, 3695, 10.1182/blood-2003-12-4250 Sephton, 2003, A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy, Obstet Gynecol, 101, 1307, 10.1016/S0029-7844(03)00340-5 Brennand, 1999, Anti-activated factor X profiles in pregnant women receiving antenatal thromboprophylaxis with enoxaparin, Acta Haematol, 101, 53, 10.1159/000040922 Casele, 1999, Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy, Am J Obstet Gynecol, 181, 1113, 10.1016/S0002-9378(99)70091-8 Dahlman, 1989, Thrombosis prophylaxis in pregnancy with use of subcutaneous heparin adjusted by monitoring heparin concentration in plasma, Am J Obstet Gynecol, 161, 420, 10.1016/0002-9378(89)90535-8 1995 2000 Gates, 2002, Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period, Cochrane Database Syst Rev, 2, CD001689 Collins, 1988, Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery, N Engl J Med, 318, 1162, 10.1056/NEJM198805053181805 Jeffery, 1990, Graduated compression stockings in the prevention of postoperative deep vein thrombosis, Br J Surg, 77, 380, 10.1002/bjs.1800770407 Greer, 2002, Exploring the role of low-molecular-weight heparins in pregnancy, Semin Thromb Hemost, 28, 25, 10.1055/s-2002-34072 Eldor, 2002, The use of low-molecular-weight heparin for the management of venous thromboembolism in pregnancy, Eur J Obstet Gynecol Reprod Biol, 104, 3, 10.1016/S0301-2115(02)00239-7 Greer, 2001, Management of venous thromboembolism in pregnancy, Best Pract Res Clin Obstet Gynaecol, 15, 583, 10.1053/beog.2001.0202 Bonnar, 2003, Venous thromboembolism in pregnancy, 217 Bonnar, 1999, Can more be done in obstetric and gynecologic practice to reduce morbidity and mortality associated with venous thromboembolism?, Am J Obstet Gynecol, 180, 784, 10.1016/S0002-9378(99)70648-4 Rosendaal, 1999, Risk factors for venous thrombotic disease, Thromb Haemost, 82, 610, 10.1055/s-0037-1615887 Conard, 2003, Inherited thrombophilia and gestational venous thromboembolism, Semin Thromb Hemost, 29, 131, 10.1055/s-2003-38828 Friederich, 1996, Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis, Ann Intern Med, 125, 955, 10.7326/0003-4819-125-12-199612150-00003 Dizon-Townson, 2005, The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus, Obstet Gynecol, 106, 517, 10.1097/01.AOG.0000173986.32528.ca Riyazi, 1998, Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study, Eur J Obstet Gynecol Reprod Biol, 80, 49, 10.1016/S0301-2115(98)00083-9 Brenner, 2000, Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin, Thromb Haemost, 83, 693, 10.1055/s-0037-1613894 Ogueh, 2001, Outcome of pregnancy in women with hereditary thrombophilia, Int J Gynaecol Obstet, 74, 247, 10.1016/S0020-7292(01)00447-7 Kupferminc, 2001, Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias, Hypertens Pregnancy, 20, 35, 10.3109/10641950109152640 Grandone, 2002, Preventing adverse obstetric outcomes in women with genetic thrombophilia, Fertil Steril, 78, 371, 10.1016/S0015-0282(02)03222-3 Brenner, 2003, Enoxaparin treatment improves the gestational outcome of pregnant women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study, Blood, 102, 43A Paidas, 2004, Does heparin therapy improve pregnancy outcome in patients with thrombophilias?, J Thromb Haemost, 2, 1194, 10.1111/j.1538-7836.2004.00784.x Walker, 2003, Heparin for pregnant women with acquired or inherited thrombophilias, Cochrane Database Syst Rev, 2, CD003580 Di Nisio, 2005, Anticoagulants for the treatment of recurrent pregnancy loss in women without antiphospholipid syndrome, Cochrane Database Syst Rev, 2, CD004734 Fausett, 2001, Heparin-induced thrombocytopenia is rare in pregnancy, Am J Obstet Gynecol, 185, 148, 10.1067/mob.2001.114690 Lepercq, 2001, Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies, BJOG, 108, 1134 Lagrange, 2002, Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra) in the dually perfused human cotyledon in vitro, Thromb Haemost, 87, 831, 10.1055/s-0037-1613092 Taylor, 2001, Successful use of heparinoids in a pregnancy complicated by allergy to heparin, BJOG, 108, 1011 Aijaz, 2001, Management of heparin allergy in pregnancy, Am J Hematol, 67, 268, 10.1002/ajh.1129 Krishnamurthy, 1999, Catheter-directed thrombolysis for thromboembolic disease during pregnancy: a viable option, J Matern Fetal Med, 8, 24 Henrich, 2001, Acute iliac vein thrombosis in pregnancy treated successfully by streptokinase lysis: a case report, J Perinat Med, 29, 155, 10.1515/JPM.2001.021 Yap, 2002, Thrombolysis for acute massive pulmonary embolism during pregnancy, Int J Cardiol, 82, 193, 10.1016/S0167-5273(01)00602-7 Grand, 1996, Ilio-femoral vein thrombosis treated with tissue plasminogen activator in a pregnant woman, Ann Cardiol Angeiol (Paris), 45, 517 Flossdorf, 1990, Successful treatment of massive pulmonary embolism with recombinant tissue type plasminogen activator (rt-PA) in a pregnant woman with intact gravidity and preterm labour, Intensive Care Med, 16, 454, 10.1007/BF01711225 Patel, 2003, Thrombolysis in pregnancy, Thromb Haemost, 90, 1216, 10.1055/s-0037-1613427 Saviotti, 1997, Massive pulmonary embolism during the third trimester of pregnancy: effectiveness of thrombolytic treatment with alteplase, G Ital Cardiol, 27, 72 Niwa, 1998, Treatment of acute superior sagittal sinus thrombosis by t-PA infusion via venography—direct thrombolytic therapy in the acute phase, Surg Neurol, 49, 425, 10.1016/S0090-3019(97)00453-9 Webber, 1997, Acute infarction, intracoronary thrombolysis, and primary PTCA in pregnancy, Cathet Cardiovasc Diagn, 42, 38, 10.1002/(SICI)1097-0304(199709)42:1<38::AID-CCD12>3.0.CO;2-I Schumacher, 1997, Successful treatment of acute myocardial infarction during pregnancy with tissue plasminogen activator, Am J Obstet Gynecol, 176, 716, 10.1016/S0002-9378(97)70579-9 Rinaldi, 1999, Successful thrombolysis on an aortic valve prosthesis by plasminogen tissue activator during pregnancy, Arch Mal Coeur Vaiss, 92, 427 Anbarasan, 2001, Successful thrombolysis of prosthetic mitral valve thrombosis in early pregnancy, J Heart Valve Dis, 10, 393 Behrendt, 2002, Successful thrombolysis of St. Jude medical aortic prosthesis with tissue-type plasminogen activator in a pregnant woman: a case report, Cardiol Rev, 10, 349, 10.1097/00045415-200211000-00007 Abbadi, 2001, Successful thrombolysis of mitral valve prosthesis by streptokinase during pregnancy, East Mediterr Health J, 7, 283, 10.26719/2001.7.1-2.283 Nassar, 2003, Sequential use of thrombolytic agents for thrombosed mitral valve prosthesis during pregnancy, J Perinat Med, 31, 257, 10.1515/JPM.2003.035 Nanas, 2001, Thrombolytic treatment for thrombosis of a mitral valve prosthesis during pregnancy, Intensive Care Med, 27, 1668, 10.1007/s001340101075 Chan, 1999, Low molecular weight heparin use during pregnancy: issues of safety and practicality, Obstet Gynecol Surv, 54, 649, 10.1097/00006254-199910000-00022 Bazzan, 2001, Low-molecular-weight heparin during pregnancy, Thromb Res, 101, V175, 10.1016/S0049-3848(00)00403-5 Pettila, 1999, Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy, Thromb Res, 96, 275, 10.1016/S0049-3848(99)00110-3 Duplaga, 2001, Dosing and monitoring of low-molecular-weight heparins in special populations, Pharmacotherapy, 21, 218, 10.1592/phco.21.2.218.34112 Chan, 2001, Antithrombotic therapy during pregnancy, Semin Perinatol, 25, 165, 10.1053/sper.2001.24899 Laposata, 1998, College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban, Arch Pathol Lab Med, 122, 799 Hague, 2001, Anticoagulation in pregnancy and the puerperium, Med J Aust, 175, 258, 10.5694/j.1326-5377.2001.tb143561.x Kearon, 1997, Management of anticoagulation before and after elective surgery, N Engl J Med, 336, 1506, 10.1056/NEJM199705223362107 2005, 69, 5 Data on file: Coagulation in Pregnancy Clinic: Medical College of Wisconsin, Wisconsin 1998-present (N = 245 patients treated with the LMWH enoxaparin prospectively) Outcome database. Borel-Derlon, 1999, Assessment of low molecular weight heparin (enoxaparin) safety during pregnancy: a retrospective study of 624 pregnancies, Thromb Haemost, 491 Dulitzki, 1996, Low-molecular-weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies, Obstet Gynecol, 87, 380, 10.1016/0029-7844(95)00452-1 Rowan, 2003, Prophylactic and therapeutic enoxaparin during pregnancy: indications, outcomes and monitoring, Aust N Z J Obstet Gynaecol, 43, 123, 10.1046/j.0004-8666.2003.00034.x Horlocker, 2003, Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation), Reg Anesth Pain Med, 28, 172 Talecris Biotherapeutics. Thrombate III 08915728: Talecris Biotherapeutics; June 2005. Lockwood, 1999, Heritable coagulopathies in pregnancy, Obstet Gynecol Surv, 54, 754, 10.1097/00006254-199912000-00004 McColl, 1999, The role of inherited thrombophilia in venous thromboembolism associated with pregnancy, BJOG, 106, 756, 10.1111/j.1471-0528.1999.tb08395.x Rosenberg, 1985, Protease inhibitors of human plasma: antithrombin III, the heparin-antithrombin system, J Med, 16, 351 Thaler, 1981, Antithrombin III deficiency and thromboembolism, Clin Haematol, 10, 369, 10.1016/S0308-2261(21)00229-0 Murano, 1980, Some properties of antithrombin-III and its concentration in human plasma, Thromb Res, 18, 259, 10.1016/0049-3848(80)90190-5 Brandt, 1981, Observations during the treatment of antithrombin-III deficient women with heparin and antithrombin concentrate during pregnancy, parturition, and abortion, Thromb Res, 22, 15, 10.1016/0049-3848(81)90304-2 Hellgren, 1982, Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin, Gynecol Obstet Invest, 14, 127, 10.1159/000299460 Colman, 2001 Weitz, 1997, Low-molecular-weight heparins, N Engl J Med, 337, 688, 10.1056/NEJM199709043371007 Toglia, 1996, Venous thromboembolism during pregnancy, N Engl J Med, 335, 108, 10.1056/NEJM199607113350207 Nelson-Piercy, 1997, Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk, Am J Obstet Gynecol, 176, 1062, 10.1016/S0002-9378(97)70403-4 McDonald, 2004, Placental fetal thrombotic vasculopathy is associated with neonatal encephalopathy, Hum Pathol, 35, 875, 10.1016/j.humpath.2004.02.014 Leistra-Leistra, 2004, Fetal thrombotic vasculopathy in the placenta: a thrombophilic connection between pregnancy complication and neonatal thrombosis?, Placenta, 25, S102, 10.1016/j.placenta.2004.01.010 Chaiworapongsa, 2002, Evidence of in vivo generation of thrombin in patients with small-for-gestational-age fetuses and pre-eclampsia, J Matern Fetal Neonat Med, 11, 362, 10.1080/jmf.11.6.362.367 Andrew, 1994, Venous thromboembolic complication (VTE) in children: first analyses of the Canadian Registry of VTE, Blood, 83, 1251, 10.1182/blood.V83.5.1251.1251 Heller, 2000, Abdominal venous thrombosis in neonates and infants: role of prothrombotic risk factors—a multicentre case-control study, Br J Haematol, 111, 534, 10.1046/j.1365-2141.2000.02349.x Tabbutt, 1994, Multiple thromboses in a premature infant associated with maternal phospholipid antibody syndrome, J Perinatol, 14, 66